Adnan M. Dahdul, M.D. - 719607 - 05/15/2026
The FDA issued a Bioresearch Monitoring (BIMO) communication to Clinical Investigator Adnan M. Dahdul, M.D., dated May 15, 2026. This action is categorized under biologics oversight.
This affects clinical investigators, sponsors of biologics-related clinical trials, and clinical research oversight departments.
The issuance of a BIMO-related document suggests that a regulatory inspection or review of clinical trial conduct has taken place. While the specific nature of the findings is not detailed in the source, such actions typically relate to compliance with Good Clinical Practice (GCP) or investigator responsibilities. This may impact the reliability of clinical data submitted for biologics licensing.
Clinical operations teams should verify the status of this investigator if they are involved in ongoing or planned biologics trials. Quality assurance should consider auditing data generated by this investigator to ensure compliance with GCP and protocol requirements.